Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study

Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Juan Besalduch(Hospital Universitario Son Dureta), César Sanz-Rodrı́guez(Merck Biopharma Co., Ltd. (Japan)), María‐Jesús Pascual(Hospital Doctor José Molina Orosa), Arancha Bermúdez(Marqués de Valdecilla University Hospital), Montserrat Rovira(Humanitas University), G Nocea(MSD (Spain))
Current Medical Research and Opinion
March 31, 2005
10.1185/030079905x43631
Cited by 18

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
|Blood|2008|957